Trevi Therapeutics Schedules Conference Call to Discuss Results
Trevi Therapeutics, Inc. (NASDAQ: TRVI) has announced an upcoming conference call and webcast to share the topline results from their Phase 2b CORAL trial, which evaluates Haduvio for treating chronic cough related to idiopathic pulmonary fibrosis (IPF).
Details of the Conference Call and Webcast
The scheduled conference call will take place soon, allowing stakeholders to gain insights into the latest findings. It will be accessible through a live webcast featuring audio alongside presentation slides, providing an in-depth overview at the time of the meeting.
Understanding Idiopathic Pulmonary Fibrosis and Chronic Cough
Idiopathic pulmonary fibrosis is a severe lung condition affecting approximately 140,000 patients in the U.S. An overwhelming number of these patients, up to 85%, suffer from chronic cough, significantly impacting their day-to-day lives. The profound implications of chronic cough can involve over 1,500 episodes per day, affecting the mental and physical well-being of patients and increasing risks of disease progression or lung transplantation.
Trevi Therapeutics and Haduvio's Role in Treatment
Trevi Therapeutics is at the forefront of addressing this debilitating condition with Haduvio, an investigational therapy that stands as the only treatment with a statistically significant reduction in cough frequency observed during clinical trials. This novel medication operates on the cough reflex arc, engaging opioid receptors to modulate the persistent urge to cough.
Looking Ahead: What's Next for Trevi Therapeutics?
In continuing its mission to enhance the quality of life for patients, Trevi Therapeutics remains committed to further developing Haduvio, which has yet to be evaluated by any regulatory body for its safety and efficacy. This initiative exemplifies the company's dedication to transforming treatment methodologies for chronic coughs associated with IPF and refractory chronic coughs.
About Trevi Therapeutics, Inc.
As a clinical-stage biopharmaceutical firm, Trevi Therapeutics, Inc. focuses on creating innovative therapies such as Haduvio. Demonstrating substantial promise in clinical trials, Haduvio offers a hopeful perspective for many individuals suffering from chronic coughs linked to IPF and RCC. The success of this undertaking may usher in new standards for treating chronic cough symptoms effectively.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to discuss the topline results of the Phase 2b CORAL trial for Haduvio in treating chronic cough associated with IPF.
How prevalent is chronic cough in patients with IPF?
Chronic cough affects about 85% of patients diagnosed with idiopathic pulmonary fibrosis.
What are the implications of chronic cough for IPF patients?
Chronic cough can lead to a decline in the quality of life, increase health risks, and may complicate treatment outcomes for patients with IPF.
What is Haduvio?
Haduvio is an investigational therapy being developed to reduce cough frequency in patients with chronic cough linked to idiopathic pulmonary fibrosis.
When will the results from the CORAL trial be available?
The results from the Phase 2b CORAL trial will be shared during the conference call scheduled shortly.
